Raloxifene vs Sermorelin
FDA Approved vs Well Studied
monitor Mechanism-based · 47% Both Raloxifene and Sermorelin act on estrogen receptors. Receptor competition may reduce effectiveness of one or both. Using multiple SERMs simultaneously is generally not recommended — choose one.
Molecular Data
Raloxifene Sermorelin
Weight 473.58 Da 3,358 Da
Half-life ~28 hours 10-12 minutes
Chain — 29 amino acids
Type Benzothiophene-derived selective estrogen receptor modulator GHRH analog
Key Benefits
Raloxifene
01 Superior breast tissue estrogen receptor antagonism makes it the preferred SERM for gynecomastia reversal
02 No estrogen agonist activity in the uterus, avoiding the endometrial risks associated with tamoxifen
03 Estrogen agonist activity in bone preserves bone mineral density and reduces fracture risk
04 Lower overall thromboembolic risk compared to tamoxifen
05 Metabolized via glucuronidation rather than CYP2D6, avoiding the drug interaction concerns that affect tamoxifen
06 Simple once-daily oral dosing with a manageable 28-hour half-life
07 FDA-approved with decades of clinical safety data in postmenopausal women
Sermorelin
01 FDA-proven efficacy
02 Maintains natural GH pulsatile patterns
03 Preserves pituitary function
04 1.26kg lean mass increase documented in elderly
05 IGF-1 mediated anabolic effects
06 Allows natural feedback regulation
Dosing Protocols
Raloxifene
60mg oral daily / Once daily
Sermorelin
200-300mcg per dose (up to 500mcg for athletic performance) / Once daily at bedtime (aligns with natural GH pulse)
Anti-aging/Longevity 200-300mcg Once at bedtime
Athletic Performance 300-500mcg Once at bedtime
Body Composition 200mcg 5 days weekly
Combination Therapy 200mcg + GHRP Once daily
Side Effects
Raloxifene
Hot flashes and increased sweating
Leg cramps and muscle spasms
Joint pain or stiffness
Peripheral edema (mild swelling in extremities)
Flu-like symptoms during initial weeks
Sermorelin
Injection site reactions (16.7% of patients - generally mild)
Nasal irritation (intranasal route)
Contraindications
History of deep vein thrombosis, pulmonary embolism, retinal vein thrombosis, or other venous thromboembolic events
Active or past history of stroke or transient ischemic attack
Known hypersensitivity to raloxifene hydrochloride or any excipients
Pregnancy or planned pregnancy (category X -- contraindicated)
Prolonged immobilization (e.g., post-surgical recovery, extended bed rest) due to elevated DVT risk
Severe hepatic impairment
Active malignancy
Pituitary tumors
Pregnancy
Research Evidence
Raloxifene Sermorelin
Status FDA Approved Well Studied
References 4 studies 5 studies
Latest — November 2024
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.